Nasdaq-listed MEI Pharma is reportedly planning to allocate $100 million to Litecoin (LTC) as part of its treasury reserves. This move signals a growing trend of publicly traded companies diversifying their holdings with cryptocurrencies beyond Bitcoin. While official statements from MEI Pharma are awaited, the news highlights Litecoin's potential as a viable corporate treasury asset due to its established network and liquidity. This decision could inspire other companies to explore integrating Litecoin into their financial strategies, potentially driving further adoption of the cryptocurrency. Holding LTC can offer a hedge against inflation and diversification benefits, aligning with modern corporate treasury management principles. The impact of this significant investment on Litecoin's price and market perception remains to be seen, but the news underscores the increasing acceptance of cryptocurrencies in the traditional financial world. ```

#BTC